The R&D pipeline reflects our long-term commitment to driving change to defeat obesity, haemophilia, growth disorders and other serious chronic diseases
Facts and figures specific to our Research & Development organisation
We have teamed up with the International Red Cross and Red Crescent Movement to solve the challenge of delivering care to vulnerable populations displaced by conflict.
Click through to find the answers to some of our more frequently asked questions on sustainability and responsible business practices.
We are driven by science, innovation and research and strive to share our knowledge with the global community.
Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and bod ... Read more
Novo Nordisk announces plans to transform its approach to Research & Development ... Read more
Oral semaglutide provides superior HbA1c and weight reductions versus placebo in ... Read more
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose respons ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Carnegie Diabetes Seminar, Copenhagen
Bernstein Strategic Decisions Conference, London
JP Morgan Milan Investor Forum, Milan
EASD Annual Congress, Berlin
Take an advanced view of the Novo
Click here to find further information
Link to conference call and presentation
Read about Novo
Nordisk – A focused healthcare company
See relevant content for private
Download relevant Investor Relations material
Peter Hugreffe AnkersenHead of Investor Relations
Anders Mikkelsen Investor Relations Manager
Valdemar Borum Svarrer Investor Relations Manager
Kristoffer Due Berg Investor Relations Manager
Chilie Thomsen Investor Relations Coordinator
up to receive company announcements.
Link to webcast and presentation